USA flag logo/image

An Official Website of the United States Government

Selective MRTF/SRF-Transcription Inhibitors: Novel Anti-fibrotics for IPF

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R43AI106166
Solicitation Year:
2013
Solicitation Topic Code:
NIAID
Solicitation Number:
PA12-088
Small Business Information
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: Selective MRTF/SRF-Transcription Inhibitors: Novel Anti-fibrotics for IPF
Agency: HHS
Contract: 1R43AI106166-01A1
Award Amount: $287,766.00
 

Abstract:

DESCRIPTION: Antibiotic resistance among common bacterial pathogens is a serious public health problem as it compromises our ability to treat infectious disease. The resistance problem is compounded by the relative lack of discovery of new antibiotics, especially those with novel mechanisms of action. Over the past several years Promiliad Biopharma has been developing new inhibitors that target the enzyme dihydrofolate reductase as a method of treatment for pathogenic bacteria, fungi and protozoa. Throughour efforts and those of our collaborators, largely funded by STTR grants, we have discovered a class of antifolates characterized by a 2, 4- diaminopyrimidine and a biaryl domain linked through a three-atom propargyl bridge. This class of molecules is animportant lead in the discovery of a new treatment for infectious disease. The current class of compounds, while potent antibacterial agents with activity against antibiotic resistant pathogens, currently lack sufficient metabolic stability. These compounds have short in vivo (and in vitro) half-lives which make progression to lead compound status somewhat difficult. We have found that by substituting a key fragment of the structure with a non-metabolizable bioisostere we can retain potency against a rangeof Gram positive pathogens while greatly improving selectivity and metabolic half-life. The goal of this project is o design, synthesize and assay additional bioisosteric analogs which display similar or better improvements in potency, metabolism and physical properties. Our goal in this Phase I application is to obtain a clear lead candidate. A Phase II project continuing from this work would then conduct IND-enabling experiments with the clear goal of filing an IND application. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: The ability to treat infections has become compromised by growing resistance to current antibiotics and has become a serious threat to public health. The significance of the threat is greater as there have been fewer antibiotics being approved for use in recent years and the discovery of a new class of antibiotic is a rare event. By employing medicinal chemistry we have been able to develop a set of second generation folate antibiotics based upon the structure of trimethoprim. These compounds are active against a range of pathogens including methicillin-resistant Staphylococcus aureus (MRSA). This project seeks to develop a clear lead candidate that will undergo preclinical evaluation with the ultimate goal of entering clinical trials.

Principal Investigator:

Nigel D. Priestley
406-243-6251
nigel.d.priestley@mail.promiliad.co

Business Contact:

Dana E. Warren
406-864-0022
dana.e.warren@mail.promiliad.com
Small Business Information at Submission:

PROMILIAD BIOPHARMA, INC.
ALBERTON, MT 59820-0010

EIN/Tax ID: 148128441
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No